% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Langen:834118,
author = {Langen, Karl-Josef and Stoffels, Gabriele and Filss,
Christian and Heinzel, Alexander and Stegmayr, Carina and
Lohmann, Philipp and Willuweit, Antje and Neumaier, Bernd
and Mottaghy, Felix M. and Galldiks, Norbert},
title = {{I}maging of amino acid transport in brain tumours:
{P}ositron emission tomography with {O}-(2-[ 18
{F}]fluoroethyl)- {L} -tyrosine ({FET})},
journal = {Methods},
volume = {130},
issn = {1046-2023},
address = {Orlando, Fla.},
publisher = {Academic Press},
reportid = {FZJ-2017-04118},
pages = {124-134},
year = {2017},
abstract = {The assessment of cerebral gliomas using magnetic resonance
imaging (MRI) provides excellent structural images but
cannot solve all diagnostic problems satisfactorily. The
differentiation of tumour tissue from non-neoplastic changes
may be difficult especially in the post-treatment phase. In
recent years, positron emission tomography (PET) using
radiolabelled amino acids has gained considerable interest
as an additional tool to improve the diagnosis of cerebral
gliomas and brain metastases. A key step for this
advancement was the development of the F-18 labelled amino
acid O-(2-[18F]fluoroethyl)-L-tyrosine (FET) which has
spread rapidly in the last decade and replaced carbon-11
labelled amino acid tracers such as 11C-methyl-L-methionine
(MET) in many centres in Europe. FET can be produced with
high efficiency and distributed in a satellite concept like
2-[18F]fluoro-2-deoxy-D-glucose (FDG). Furthermore, FET
exhibits favourable properties such as high in vivo
stability, high tumour to background contrast and tissue
specific tracer kinetics, which provides additional
information for tumour grading or differential diagnosis.
The Response Assessment in Neuro-Oncology (RANO) working
group — an international effort to develop new
standardized response criteria for clinical trials in brain
tumours — has recently recommended the additional use of
amino acid PET imaging for brain tumour management. FET PET
can provide important diagnostic information in crucial
situations such as the definition of biopsy site, the
delineation of cerebral gliomas for therapy planning,
sensitive monitoring of treatment response and an improved
differentiation of tumour recurrence from treatment-related
changes. In this article the basic information,
methodological aspects and the actual status of clinical
application of FET PET are reviewed.},
cin = {INM-4 / INM-3 / INM-5 / JARA-BRAIN},
ddc = {540},
cid = {I:(DE-Juel1)INM-4-20090406 / I:(DE-Juel1)INM-3-20090406 /
I:(DE-Juel1)INM-5-20090406 / $I:(DE-82)080010_20140620$},
pnm = {573 - Neuroimaging (POF3-573)},
pid = {G:(DE-HGF)POF3-573},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28552264},
UT = {WOS:000414879700014},
doi = {10.1016/j.ymeth.2017.05.019},
url = {https://juser.fz-juelich.de/record/834118},
}